https://mindmedicinelaw.com/briefing/electrical-stimulation-as-ketamine-alternative-in-neurons-20260801-114Psychedelic Research Journalen2026-05-08T15:04:58.791624+00:00Electrical Stimulation as Ketamine Alternative in Neuronselectrical stimulation, ketamine alternative, dopaminergic neurons, BDNF signaling, mTOR signaling, depression treatment, non-drug therapies, neuroscience research, clinical trials, mental health innovationhttps://mindmedicinelaw.com/briefing/electrophysiological-insights-into-psychedelics-implications-for-trials-20260601-134Psychedelic Research Journalen2026-05-08T15:05:09.846060+00:00Electrophysiological Insights into Psychedelics: Implications for Trialspsychedelic research, electrophysiology, clinical trials, biomarkers, brain activity, mental health treatment, neural plasticity, EEG, MEG, therapeutic potentialhttps://mindmedicinelaw.com/briefing/psychedelic-assisted-therapy-for-youth-clinical-and-ethical-dimensions-20260508-1614Psychedelic Research Journalen2026-05-09T15:05:34.805170+00:00Psychedelic-Assisted Therapy for Youth: Clinical and Ethical Dimensionspsychedelic-assisted therapy, youth mental health, clinical trials, psilocybin, MDMA, ethical considerations, family involvement, psycholytic approach, mental illness, adolescent therapyhttps://mindmedicinelaw.com/briefing/arketamine-s-potential-in-depression-treatment-a-new-frontier-20260508-1657Psychedelic Research Journalen2026-05-09T15:05:08.207418+00:00Arketamine's Potential in Depression Treatment: A New Frontierarketamine, esketamine, depression treatment, NMDA receptor, clinical trials, antidepressant efficacy, pharmaceutical research, treatment protocols, mental health, drug developmenthttps://mindmedicinelaw.com/briefing/r-ketamine-s-surprising-antidepressant-potential-20260508-1656Psychedelic Research Journalen2026-05-09T15:04:54.788627+00:00R-Ketamine's Surprising Antidepressant Potentialr-ketamine, s-ketamine, antidepressant effects, nmda receptor, depression treatment, clinical trials, pharmacology, arketamine, esketamine, mental healthhttps://mindmedicinelaw.com/briefing/psilocybin-shows-promise-in-reducing-cocaine-use-20260508-1724Psychedelic Research Journalen2026-05-09T15:04:38.717021+00:00Psilocybin Shows Promise in Reducing Cocaine Usepsilocybin, cocaine addiction, clinical trial, substance use disorder, psychedelic therapy, neuroplasticity, FDA, Controlled Substances Act, serotonin receptors, addiction treatmenthttps://mindmedicinelaw.com/briefing/ketamine-s-cognitive-effects-in-depression-implications-for-clinical-practice-20260508-1562Psychedelic Research Journalen2026-05-08T22:03:14.501488+00:00Ketamine's Cognitive Effects in Depression: Implications for Clinical Practiceketamine, treatment-resistant depression, cognitive effects, clinical guidelines, NMDA receptor antagonist, systematic review, patient safety, treatment protocols, depression treatment, neuroscience researchhttps://mindmedicinelaw.com/briefing/psilocybin-reduces-cocaine-use-new-clinical-trial-insights-20260508-1245Psychedelic Research Journalen2026-05-08T15:04:36.636413+00:00Psilocybin Reduces Cocaine Use: New Clinical Trial Insightspsilocybin, cocaine addiction, clinical trial, Filament Health, psychedelic research, intellectual property, addiction treatment, serotonin receptors, FDA, Schedule I substancehttps://mindmedicinelaw.com/briefing/louisiana-approves-psychedelic-therapy-pilot-program-20260508-1247Psychedelic Research Journalen2026-05-08T15:04:10.535328+00:00Louisiana Approves Psychedelic Therapy Pilot Programpsychedelic therapy, Louisiana policy, opioid settlement funds, mental health treatment, public health initiative, psychedelic research, legal challenges, clinical trials, state-funded programs, market opportunitieshttps://mindmedicinelaw.com/briefing/louisiana-advances-psychedelic-therapy-legislation-with-unanimous-bill-20260507-1725Psychedelic Research Journalen2026-05-09T15:04:24.828810+00:00Louisiana Advances Psychedelic Therapy Legislation with Unanimous Billlouisiana psychedelic therapy, psychedelic legislation, mental health treatment, drug policy reform, psychedelic research, therapeutic psychedelics, state healthcare policy, legal framework for psychedelics, alternative mental health treatments, psychedelic therapy programhttps://mindmedicinelaw.com/briefing/new-ptsd-memory-model-implications-for-mdma-therapy-20260507-825Psychedelic Research Journalen2026-05-08T16:12:07.187521+00:00New PTSD Memory Model: Implications for MDMA TherapyPTSD memory dynamics, MDMA-assisted therapy, pathological crystallization, traumatic memory reactivation, clinical trials, exposure-based treatments, neurobiological parameters, Schrödinger–REK–RGB frameworkhttps://mindmedicinelaw.com/briefing/psilocybin-trial-for-cocaine-use-disorder-a-decade-in-progress-20260507-1408Psychedelic Research Journalen2026-05-08T16:11:40.006691+00:00Psilocybin Trial for Cocaine Use Disorder: A Decade in Progresspsilocybin, cocaine use disorder, psychedelic research, addiction treatment, clinical trials, public health, serotonin receptors, drug policy, mental health, Peter Hendrickshttps://mindmedicinelaw.com/briefing/lawmakers-urge-fda-to-expedite-psychedelic-therapy-approvals-20260507-1082Psychedelic Research Journalen2026-05-07T22:03:32.043190+00:00Lawmakers Urge FDA to Expedite Psychedelic Therapy ApprovalsFDA, psychedelic therapies, bipartisan support, drug approval process, mental health treatment, psilocybin, MDMA, clinical trials, regulatory landscape, market growthhttps://mindmedicinelaw.com/briefing/psilocybin-s-potential-in-treating-cocaine-addiction-ama-study-20260507-1084Psychedelic Research Journalen2026-05-07T22:03:24.193054+00:00Psilocybin's Potential in Treating Cocaine Addiction: AMA Studypsilocybin, cocaine addiction, substance use disorder, American Medical Association, psychedelic therapy, clinical trials, public health policy, serotonin receptors, FDA, Schedule I substancehttps://mindmedicinelaw.com/briefing/mdma-use-in-older-adults-diagnostic-challenges-and-risks-20260506-828Psychedelic Research Journalen2026-05-08T16:12:19.617924+00:00MDMA Use in Older Adults: Diagnostic Challenges and RisksMDMA, older adults, hyponatremia, psychedelic therapy, diagnostic challenges, emergency medicine, self-directed therapy, psychedelic research, clinical trials, public healthhttps://mindmedicinelaw.com/briefing/fda-awards-priority-review-vouchers-to-psychedelic-firms-20260506-1244Psychedelic Research Journalen2026-05-08T15:04:23.897167+00:00FDA Awards Priority Review Vouchers to Psychedelic FirmsFDA, priority review vouchers, Otsuka, Compass Pathways, Usona Institute, psychedelic therapies, drug approval, mental health, regulatory review, investment in psychedelicshttps://mindmedicinelaw.com/briefing/cns-drug-innovation-global-achievements-and-barriers-20260505-1490Psychedelic Research Journalen2026-05-08T22:03:25.360557+00:00CNS Drug Innovation: Global Achievements and BarriersCNS drug development, psychedelic therapies, PTSD treatment, depression treatment, regulatory modernization, neuropsychopharmacology, clinical trials, AI in drug development, global access to medicine, biomarker-enabled trialshttps://mindmedicinelaw.com/briefing/epik-biosciences-launches-ketamine-therapies-initiative-20260505-487Psychedelic Research Journalen2026-05-08T16:12:39.409260+00:00EPIK Biosciences Launches Ketamine Therapies Initiativeketamine therapies, EPIK Biosciences, mental health treatment, psychedelic research, clinical trials, addiction therapy, public health, psychedelic market, drug policy, neuroplasticityhttps://mindmedicinelaw.com/briefing/esketamine-in-trd-pilot-study-on-psychotherapy-s-role-20260505-742Psychedelic Research Journalen2026-05-08T16:12:29.258505+00:00Esketamine in TRD: Pilot Study on Psychotherapy's Roleesketamine, treatment-resistant depression, psychotherapy, pharmacogenetics, clinical trials, depression treatment, TRD, antidepressant response, mental health, personalized medicinehttps://mindmedicinelaw.com/briefing/phase-3-kop-antagonists-trials-fail-in-trd-treatment-20260502-745Psychedelic Research Journalen2026-05-08T16:12:47.995391+00:00Phase 3 KOP Antagonists Trials Fail in TRD Treatmentkappa-opioid receptor, treatment-resistant depression, clinical trials, opioid antagonists, nociceptin receptor, dual receptor blockers, neuroscience, pharmaceutical development, mental health treatmenthttps://mindmedicinelaw.com/briefing/lsd-s-impact-on-white-matter-implications-for-depression-treatment-20260501-1621Psychedelic Research Journalen2026-05-09T15:05:22.190764+00:00LSD's Impact on White Matter: Implications for Depression TreatmentLSD, neuroplasticity, white matter, major depressive disorder, fractional anisotropy, psychedelic-assisted therapy, clinical research, FDA, mental health, brain connectivityhttps://mindmedicinelaw.com/briefing/fda-proposal-may-ease-path-for-psychedelic-research-devices-20260501-369Psychedelic Research Journalen2026-05-08T22:03:55.256600+00:00FDA Proposal May Ease Path for Psychedelic Research DevicesFDA, Class II devices, premarket notification, psychedelic research, clinical toxicology, 21st Century Cures Act, diagnostic tools, regulatory process, public comment, safety and efficacyhttps://mindmedicinelaw.com/briefing/trkb-mglur5-cross-talk-in-ketamine-s-synaptic-effects-20260501-643Psychedelic Research Journalen2026-05-08T22:03:44.466006+00:00TrkB/mGluR5 Cross-Talk in Ketamine's Synaptic Effectsketamine, TrkB receptor, mGluR5 receptor, synaptic metaplasticity, depression treatment, psychedelic research, mental health, clinical trials, neurosciencehttps://mindmedicinelaw.com/briefing/esketamine-vs-magnesium-post-op-pain-in-sinus-surgery-20260501-1508Psychedelic Research Journalen2026-05-08T22:03:35.301409+00:00Esketamine vs Magnesium: Post-Op Pain in Sinus Surgeryesketamine, magnesium sulfate, postoperative pain, endoscopic sinus surgery, NMDA receptor antagonists, perioperative care, anxiety, depression, randomized controlled trial, pain managementhttps://mindmedicinelaw.com/briefing/mobile-tms-for-montana-veterans-a-promising-model-20260501-856Psychedelic Research Journalen2026-05-07T22:03:41.950904+00:00Mobile TMS for Montana Veterans: A Promising Modelmobile TMS, Montana veterans, mental health care, rural healthcare, transcranial magnetic stimulation, veterans PTSD, neuromodulation access, mobile medical unit, mental health disparities, telehealthhttps://mindmedicinelaw.com/briefing/cbt-and-psilocybin-promising-results-for-depression-20260430-649Psychedelic Research Journalen2026-05-08T22:04:04.231513+00:00CBT and Psilocybin: Promising Results for Depressionpsilocybin, cognitive behavioral therapy, depression treatment, psychedelic research, mental health, pilot trial, neuroplasticity, treatment protocols, clinical trials, regulatory challengeshttps://mindmedicinelaw.com/briefing/eeg-biomarker-predicts-ketamine-response-in-depression-20260427-429Psychedelic Research Journalen2026-05-07T22:03:52.221266+00:00EEG Biomarker Predicts Ketamine Response in Depressionketamine, treatment-resistant depression, EEG biomarker, thalamic filter model, AR1, depression treatment, personalized medicine, neuroscience, clinical trials, antidepressant responsehttps://mindmedicinelaw.com/briefing/brain-markers-predict-ketamine-response-in-depression-20260425-631Psychedelic Research Journalen2026-05-07T22:04:00.068646+00:00Brain Markers Predict Ketamine Response in Depressionketamine, treatment-resistant depression, brain markers, magnetic susceptibility, R2*, personalized therapy, antidepressant response, clinical trials, neuroscience, psychedelic researchhttps://mindmedicinelaw.com/briefing/psilocybin-s-impact-on-brain-connectivity-in-meth-use-disorder-20260424-613Psychedelic Research Journalen2026-05-08T15:04:48.229414+00:00Psilocybin's Impact on Brain Connectivity in Meth Use Disorderpsilocybin, brain connectivity, methamphetamine use disorder, addiction treatment, clinical trials, neuroscience, psychedelic therapy, functional MRIhttps://mindmedicinelaw.com/briefing/ketamine-s-role-in-pediatric-sedation-clinical-insights-20260424-483Psychedelic Research Journalen2026-05-07T22:04:10.553623+00:00Ketamine's Role in Pediatric Sedation: Clinical Insightsketamine, pediatric sedation, mechanically ventilated children, clinical guidelines, anesthesia, critical care, meta-analysis, safety, efficacy, future research